Osteoporosis Agents: Prolia and Denosumab Biosimilars
Customize your policy alerts
Sign up for all Mass General Brigham Health Plan policy alerts
Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization for Prolia and denosumab biosimilars under the MassHealth medical benefit for osteoporosis, glucocorticoid-induced osteoporosis, and bone-mass preservation during selected high-risk cancer therapies. Clinical documentation, preferred-product sequencing, and renewal criteria apply.
Osvyrti (denosumab-desu) was added as an additional preferred denosumab biosimilar and requires prior authorization through both the pharmacy and medical benefits.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.